daratumumab,talquetamab,teclistamab
genmab,janssen
[]
dr. yael cohen presents combination teclistimab and talquetembab in triple class exposed, median 4 prior lines, 1/3rd soft tissue emd. 96% orr! 86% in emd. safety profile similar to monotherapy! fantastic! 
Multiple Myeloma Oncologist